



## Vaccines in Farm Animals

Guest Editors:

**Dr. David Arranz-Solís**

**Dr. Yanina Paola Hecker**

**Dr. Valentin Pérez**

Deadline for manuscript  
submissions:

**closed (31 July 2022)**

### Message from the Guest Editors

Dear Colleagues,

In this special issue we focus on the development, characterization, field trials and efficiency tests of vaccines aimed at stopping or preventing diseases affecting animals and humans, with an especial interest in those related to livestock.

To this end, we invite you to submit an original research or review to this Special Issue covering (but not limited to) the following topics:

- a) Vaccines against protozoan parasites (e.g. *Toxoplasma*, *Neospora*, *Eimeria*, *Theileria*, *Tritrichomonas*...)
- b) Vaccines against diseases affecting ruminants, with especial interest in those vertically transmitted or causing abortion (protozoans, viruses, bacteria...)
- c) Vaccines against diseases transmitted to humans through animal products (meat, milk, eggs...)
- d) Recombinant or inactivated vaccine trials in livestock (cattle, sheep, goat, poultry, pigs...)
- e) Vaccines based on genetically modified organisms affecting animals and humans (knockout, exogenous expression of heterologous proteins/antigens)

We are looking forward to your interesting manuscript and do not hesitate to contact us should you require further information.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)